NK/T-CELL LYMPHOMA (NKTCL) TREATMENT
AT SYSUCC AND CHINESE CENTRES

NK/T-cell lymphoma is uncommon enough in Europe and North America that many oncologists rarely see a case, and standard B-cell lymphoma protocols do not work well for this disease. CHOP-style regimens have repeatedly shown poor results in NK/T-cell lymphoma because the cancer cells express high levels of P-glycoprotein, which pumps anthracyclines and several other chemotherapy drugs back out of the cell. Asparaginase, which is not a P-glycoprotein substrate, became the foundation of effective therapy, and most of the regimens that define current practice were developed or validated in Asian centres. Sun Yat-sen University Cancer Center in Guangzhou is one of the highest-volume cancer hospitals in the world, with a specialised lymphoma programme that has contributed major clinical trials in NK/T-cell lymphoma, including work on the P-GEMOX regimen, sandwich chemoradiotherapy in early-stage disease, prognostic models, EBV DNA monitoring, and immune checkpoint inhibitor strategies in relapsed disease. Other major Chinese centres, including the Chinese Academy of Medical Sciences and National Cancer Center in Beijing, Fudan University Shanghai Cancer Center, Tianjin Medical University Cancer Institute, and Peking University Cancer Hospital, also see large NK/T-cell lymphoma volumes and run active trials. China is most relevant for NK/T-cell lymphoma when local options are limited, when relapse has occurred after first-line treatment, when anti-PD-1 antibodies or trial-stage cellular therapies are being considered, or when families want their case reviewed by physicians who manage this disease regularly rather than rarely.

Extranodal NK/T-cell lymphoma, nasal type, arises from natural killer cells or, less commonly, cytotoxic T cells, and is almost universally associated with Epstein-Barr virus. The cancer cells express CD2, cytoplasmic CD3 (CD3 epsilon), CD56 in most cases, and cytotoxic markers such as TIA-1, granzyme B, and perforin, while typically lacking surface CD3 and other mature T-cell markers. EBV is detected within tumour cells using EBER in situ hybridisation, which is essential for diagnosis. The disease most often presents in the upper aerodigestive tract, especially the nasal cavity, paranasal sinuses, palate, and nasopharynx, where it can cause destructive midfacial lesions. Less commonly, it presents at non-nasal sites including skin, gastrointestinal tract, testis, soft tissue, or as disseminated disease with bone marrow involvement and high EBV viral load. Non-nasal disease and disseminated presentations generally behave more aggressively. Several prognostic systems guide treatment intensity, including the original IPI, the Korean prognostic index for NK/T-cell lymphoma (KPI), the prognostic index for natural killer lymphoma (PINK), and the PINK-E model that incorporates baseline EBV DNA. Plasma EBV DNA is also widely used during and after treatment as a marker of disease activity, particularly at experienced Asian centres.

Early-Stage Nasal Disease For limited-stage nasal disease, the cornerstone of treatment is involved-site or involved-field radiotherapy combined with asparaginase-based chemotherapy. Several integrated approaches are used, including sandwich therapy with chemotherapy followed by radiotherapy and additional chemotherapy, concurrent chemoradiotherapy, and sequential chemotherapy followed by radiotherapy. Radiation doses are typically in the moderate to high range, given the relative radiosensitivity of this lymphoma. Outcomes in early-stage disease have improved substantially with these integrated regimens, and many patients can achieve long-term remission. Choice between sandwich, concurrent, and sequential approaches depends on tumour bulk, local invasion, patient fitness, and centre experience. Advanced and Disseminated Disease For advanced-stage disease, including stage III, stage IV, and non-nasal presentations, asparaginase-based combination chemotherapy is the foundation of treatment. The most widely used regimens include P-GEMOX (gemcitabine, oxaliplatin, and pegaspargase), which is well tolerated and is one of the most commonly used regimens in China; SMILE (steroid, methotrexate, ifosfamide, L-asparaginase, etoposide), an older more intensive regimen with established activity but higher toxicity; AspaMetDex (asparaginase, methotrexate, dexamethasone), which is shorter and outpatient-suited; and DDGP or modified DDGP (dexamethasone, cisplatin, gemcitabine, pegaspargase), developed and refined in Chinese trials. Selection between these regimens depends on disease bulk, patient fitness, organ function, and centre experience. Autologous stem cell transplant in first complete remission is considered for high-risk patients, especially those with advanced-stage disease, high EBV DNA, or PINK or PINK-E intermediate to high-risk scores. Allogeneic stem cell transplant is generally reserved for relapsed patients or selected very-high-risk first-line cases. Anti-PD-1 Antibody Therapy NK/T-cell lymphoma has emerged as one of the most PD-1 responsive lymphomas. The combination of high EBV antigen load, immune evasion through PD-L1 upregulation, and a generally inflamed microenvironment makes this disease unusually sensitive to PD-1 blockade. Several Chinese-developed PD-1 inhibitors are widely used in this setting, including sintilimab, tislelizumab, toripalimab, and camrelizumab, alongside originator agents such as pembrolizumab and nivolumab in selected markets. Anti-PD-1 therapy is most established in relapsed and refractory disease, often producing durable responses including in patients who have failed asparaginase-based chemotherapy. It is increasingly being studied in earlier lines, in maintenance, and in combination with chemotherapy or histone deacetylase inhibitors such as chidamide, a Chinese-developed HDAC inhibitor used in T-cell lymphoma. Chinese trials in this space are particularly active and patients with relapsed NK/T-cell lymphoma may have meaningful trial-based options. Other Targeted and Cellular Approaches Beyond asparaginase chemotherapy, radiotherapy, and PD-1 blockade, additional options under study or in approved use in selected settings include chidamide and other HDAC inhibitors, brentuximab vedotin in CD30-positive cases, EBV-specific cytotoxic T-lymphocyte therapy, and trial-stage cellular therapies including CAR-NK and CD30 or other antigen-directed CAR-T platforms in CD30-positive variants. Several Chinese academic centres are working on EBV-directed adoptive immunotherapy specifically for NK/T-cell lymphoma.

Eligibility is always reviewed by the treating hospital and depends on multiple factors:

• Confirmed pathology of extranodal NK/T-cell lymphoma, with E

  Confirmed pathology of extranodal NK/T-cell lymphoma, with EBV positivity demonstrated by EBER in situ hybridisation

• Clear documentation of stage, anatomical site (nasal versus

  Clear documentation of stage, anatomical site (nasal versus non-nasal), and disease bulk

• Appropriate prognostic risk assessment using IPI, KPI, PINK,

  Appropriate prognostic risk assessment using IPI, KPI, PINK, or PINK-E

• Adequate organ function — liver, kidney, heart, lung — and a

  Adequate organ function — liver, kidney, heart, lung — and acceptable blood counts, especially given asparaginase-related coagulation and hepatic effects

• ECOG performance status, typically 0 to 2, depending on prot

  ECOG performance status, typically 0 to 2, depending on protocol

• No clinically significant CNS lymphoma, or treated and stabl

  No clinically significant CNS lymphoma, or treated and stable CNS disease in selected protocols

• Manageable comorbidities, including controlled hepatitis B (

  Manageable comorbidities, including controlled hepatitis B (with antiviral prophylaxis), hepatitis C, and HIV where present

• Travel fitness, particularly for early-stage disease where p

  Travel fitness, particularly for early-stage disease where prompt initiation of chemoradiotherapy is important

• Realistic plan for combined chemotherapy and radiotherapy, i

  Realistic plan for combined chemotherapy and radiotherapy, including a stay long enough to complete the integrated regimen safely

• For relapsed disease, reasonable access to anti-PD-1 therapy

  For relapsed disease, reasonable access to anti-PD-1 therapy, salvage chemotherapy, transplant evaluation, or clinical trial inclusion

Because NK/T-cell lymphoma is rare and biologically distinct, complete pathology and EBV documentation is especially important. The following are typically requested:

• Latest medical summary and treating oncologist's or haematol

  Latest medical summary and treating oncologist's or haematologist's opinion

• Original biopsy and histopathology report confirming extrano

  Original biopsy and histopathology report confirming extranodal NK/T-cell lymphoma, with site clearly stated

• IHC report including CD2, surface CD3, cytoplasmic CD3, CD4,

  IHC report including CD2, surface CD3, cytoplasmic CD3, CD4, CD5, CD7, CD8, CD56, CD30, TIA-1, granzyme B, perforin, Ki-67, and other relevant markers

• EBER in situ hybridisation result confirming EBV in tumour c

  EBER in situ hybridisation result confirming EBV in tumour cells

• Plasma or whole-blood EBV DNA quantitative result, with assa

  Plasma or whole-blood EBV DNA quantitative result, with assay details where available

• T-cell receptor gene rearrangement study where performed

  T-cell receptor gene rearrangement study where performed

• Bone marrow aspiration and biopsy report, including EBER sta

  Bone marrow aspiration and biopsy report, including EBER staining of marrow

• Flow cytometry report from blood, marrow, or tissue

  Flow cytometry report from blood, marrow, or tissue

• Recent PET CT report, ideally covering skull base to thigh,

  Recent PET CT report, ideally covering skull base to thigh, plus dedicated nasal and paranasal imaging where relevant

• MRI of the head and neck for nasal disease, including evalua

  MRI of the head and neck for nasal disease, including evaluation of orbital, intracranial, and skull base extension

• Endoscopy reports and clinical photographs of nasal or oral

  Endoscopy reports and clinical photographs of nasal or oral lesions where available

• Lumbar puncture and CSF analysis if performed

  Lumbar puncture and CSF analysis if performed

CancerFax supports NK/T-cell lymphoma cases through a structured pathway:

• Case review — diagnosis, EBV status, anatomical site, stage,

  Case review — diagnosis, EBV status, anatomical site, stage, prognostic score, prior treatments, and current disease behaviour are reviewed against the most relevant treatment options.

• Pathology and biomarker check — IHC, EBER, EBV DNA, and flow

  Pathology and biomarker check — IHC, EBER, EBV DNA, and flow cytometry reports are checked, and missing investigations are flagged before hospital review.

• Hospital and specialist matching — the case is shared with a

  Hospital and specialist matching — the case is shared with appropriate Chinese cancer centres, with attention to centre experience in this rare disease, including SYSUCC, the Chinese Academy of Medical Sciences and National Cancer Center, Fudan University Shanghai Cancer Center, Tianjin Medical University Cancer Institute, and other high-volume programmes.

• Trial matching — relevant clinical trials in anti-PD-1 combi

  Trial matching — relevant clinical trials in anti-PD-1 combinations, HDAC inhibitor combinations, EBV-directed immunotherapy, and cellular therapy platforms are identified where appropriate.

• Integrated chemoradiotherapy planning — for early-stage nasa

  Integrated chemoradiotherapy planning — for early-stage nasal disease, CancerFax helps coordinate the timing of chemotherapy and radiotherapy across the patient's stay.

• Cost and stay planning — patients receive a clear picture of

  Cost and stay planning — patients receive a clear picture of expected hospital charges, chemotherapy cycles, radiotherapy duration, monitoring, accommodation, and follow-up timelines.

• Travel and admission support — visa guidance, interpreter co

  Travel and admission support — visa guidance, interpreter coordination, hospital communication, and admission planning are handled in one pathway.

• Continuity after return home — CancerFax helps maintain comm

  Continuity after return home — CancerFax helps maintain communication between the Chinese treating team and the patient's local oncologist for follow-up scans, EBV DNA monitoring, and any further therapy.

This comparison is general. Many patients receive these regimens in sequence rather than as alternatives. Choice and dose modification depend on stage, disease bulk, fitness, organ function, and centre experience. The treating haematology team makes the final recommendation.

NK/T-cell lymphoma care, including asparaginase-based chemotherapy, integrated chemoradiotherapy, anti-PD-1 protocols, autologous and allogeneic transplant, and active clinical trials, is concentrated at major academic and specialist centres across China. Sun Yat-sen University Cancer Center in Guangzhou is one of the most recognised centres globally for this disease and has contributed extensively to the regimens and prognostic models used today. Other high-volume programmes include the Chinese Academy of Medical Sciences and National Cancer Center in Beijing, Fudan University Shanghai Cancer Center, Tianjin Medical University Cancer Institute and Hospital, Peking University Cancer Hospital, and several university-affiliated haematology units in Shanghai, Hangzhou, Chengdu, and other cities. Because NK/T-cell lymphoma is rare, even within China not every cancer centre has the same depth of experience. Centre selection matters more than country choice. Eligibility rules, regimen preferences, radiotherapy planning, and trial availability differ between hospitals. CancerFax helps match the case with a centre that fits the clinical situation, including patient stage, language and travel preferences, and trial interest.

Frequently Asked Questions

Answers to common questions from patients and families.

Structured reference data summarizing key information for this topic.